# A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

> **NCT04970693** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 64 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Oligoprogressive

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT04970693
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2021-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970693, "A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04970693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*